Correlation of anti-acetylcholine antibodies with progression of blistering disease - pemphigus
Not Applicable
- Conditions
- Health Condition 1: L100- Pemphigus vulgaris
- Registration Number
- CTRI/2019/05/018881
- Lead Sponsor
- Indian Association of Dermatology venereology and leprosy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
confirmed cases of pemphigus disease after taking informed consent.
Exclusion Criteria
Patients not willing to participate in the study
Myasthenia Gravis
Lambert-EAton syndrome
Small cell carcinoma of lung
Systemic lupus erythematosus
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Autoimmune Bullous skin disorder intensity score (ABSIS) and Pemphigus disease activity index (PDAI) will be calculated at 0, 1 and 6 months <br/ ><br>Acetylcholine antibodies will be estimated at 0, 1 and 6 months <br/ ><br>desmoglein antibodies will be estimated at 0,1 and 6 monthsTimepoint: Autoimmune Bullous skin disorder intensity score (ABSIS) and Pemphigus disease activity index (PDAI) will be calculated at 0, 1 and 6 months <br/ ><br>Acetylcholine antibodies will be estimated at 0, 1 and 6 months <br/ ><br>desmoglein antibodies will be estimated at 0,1 and 6 months
- Secondary Outcome Measures
Name Time Method tires of acetylcholine and desmoglein ELISATimepoint: baseline, 1 month and 6 months